ArticleFrontiers in immunology2025

Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma.

Lichang Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.